000119276 001__ 119276
000119276 005__ 20240228145431.0
000119276 0247_ $$2doi$$a10.18632/oncotarget.13540
000119276 0247_ $$2pmid$$apmid:27894094
000119276 037__ $$aDKFZ-2017-00062
000119276 041__ $$aeng
000119276 082__ $$a610
000119276 1001_ $$0P:(DE-HGF)0$$aMacher-Goeppinger, Stephan$$b0$$eFirst author
000119276 245__ $$aMET expression and copy number status in clear-cell renal cell carcinoma: prognostic value and potential predictive marker.
000119276 260__ $$a[S.l.]$$bImpact Journals LLC$$c2017
000119276 3367_ $$2DRIVER$$aarticle
000119276 3367_ $$2DataCite$$aOutput Types/Journal article
000119276 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1511273785_9860
000119276 3367_ $$2BibTeX$$aARTICLE
000119276 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000119276 3367_ $$00$$2EndNote$$aJournal Article
000119276 520__ $$aMultiple targeted therapy for advanced clear-cell renal cell carcinoma (RCC) has substantially improved patient outcome, but complete remission is uncommon and many tumors eventually develop resistance. Mechanistic, preclinical, and early clinical data highlight c-Met / hepatocyte growth factor receptor as a promising target for RCC therapeutic agents.We have examined MET expression, frequency of MET gene copy gains and MET gene mutation in a large, hospital-based series of renal cell carcinomas with long-term follow-up information.Out of a total of 572 clear-cell RCC, only 17% were negative for MET expression whereas 32% showed high protein levels. High MET expression and MET copy number gains were associated with an aggressive phenotype and an unfavorable patient outcome. Elevated protein levels in absence of gene amplification were not attributed to mutations, based on results of targeted next-generation sequencing.Our data reveal that clear-cell RCC with MET upregulation show an aggressive behavior and MET copy number increase is evident in a substantial percentage of patients with high-grade carcinomas and metastatic disease. Diagnostic assessment of MET expression and amplification may be of predictive value to guide targeted therapy against MET signaling in patients with clear-cell RCC.
000119276 536__ $$0G:(DE-HGF)POF3-317$$a317 - Translational cancer research (POF3-317)$$cPOF3-317$$fPOF III$$x0
000119276 588__ $$aDataset connected to CrossRef, PubMed,
000119276 7001_ $$0P:(DE-He78)8dd9fa632ca161d0ca1929a4d99cbe77$$aKeith, Martina$$b1$$udkfz
000119276 7001_ $$aEndris, Volker$$b2
000119276 7001_ $$aPenzel, Roland$$b3
000119276 7001_ $$0P:(DE-He78)55bdae24f65a1c0e58c6d721e968c3f4$$aTagscherer, Katrin$$b4$$udkfz
000119276 7001_ $$aPahernik, Sascha$$b5
000119276 7001_ $$aHohenfellner, Markus$$b6
000119276 7001_ $$aGardner, Humphrey$$b7
000119276 7001_ $$aGrüllich, Carsten$$b8
000119276 7001_ $$aSchirmacher, Peter$$b9
000119276 7001_ $$0P:(DE-He78)6c54d919bb3371b6d7f277e2c6262a4a$$aRoth, Wilfried$$b10$$eLast author$$udkfz
000119276 773__ $$0PERI:(DE-600)2560162-3$$a10.18632/oncotarget.13540$$gVol. 8, no. 1$$n1$$p1046-1057$$tOncoTarget$$v8$$x1949-2553$$y2017
000119276 909CO $$ooai:inrepo02.dkfz.de:119276$$pVDB
000119276 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bONCOTARGET : 2015
000119276 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000119276 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000119276 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000119276 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000119276 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000119276 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000119276 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000119276 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bONCOTARGET : 2015
000119276 9141_ $$y2017
000119276 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000119276 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8dd9fa632ca161d0ca1929a4d99cbe77$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000119276 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)55bdae24f65a1c0e58c6d721e968c3f4$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000119276 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6c54d919bb3371b6d7f277e2c6262a4a$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000119276 9131_ $$0G:(DE-HGF)POF3-317$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vTranslational cancer research$$x0
000119276 9201_ $$0I:(DE-He78)G150-20160331$$kG150$$lMolekulare Tumorpathologie$$x0
000119276 980__ $$ajournal
000119276 980__ $$aVDB
000119276 980__ $$aI:(DE-He78)G150-20160331
000119276 980__ $$aUNRESTRICTED